



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/705, C12N 5/10, C07K 16/28, G01N 33/563, 33/50, A61K 31/70, A01K 67/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/53062</p> <p>(43) International Publication Date: 26 November 1998 (26.11.98)</p>
<p>(21) International Application Number: PCT/CA98/00487</p> <p>(22) International Filing Date: 22 May 1998 (22.05.98)</p> <p>(30) Priority Data: 08/861,747 22 May 1997 (22.05.97) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/861,747 (CIP) Filed on 22 May 1997 (22.05.97)</p> <p>(71) Applicant (for all designated States except US): ALLELIX BIOPHARMACEUTICALS, INC. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MUNROE, Donald, G. [CA/CA]; 27 Wakefield Lane, Waterdown, Ontario L0R 2H3 (CA). VYAS, Tejal, B. [CA/CA]; 275 Riel Drive, Mississauga, Ontario L5B 3K1 (CA).</p>	<p>(74) Agents: CHARI, Santosh, K. et al.; Orange & Associates, Toronto Dominion Bank Tower, Toronto-Dominion Centre, Suite 3600, P.O. Box 190, Toronto, Ontario M5K 1H6 (CA).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. With amended claims.</p>	
<p>(54) Title: A HUMAN EDG-6 RECEPTOR HOMOLOGUE</p> <p>(57) Abstract</p> <p>An isolated nucleic acid sequence coding for an amino acid sequence for a novel human EDG-6 receptor homologue is provided. Also provided are purified human EDG-6 receptor polypeptides derived from the nucleic acid and methods and transgenic animals therefor.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A HUMAN EDG-6 RECEPTOR HOMOLOGUE

FIELD OF THE INVENTION

5 The present invention is in the field of molecular biology; more particularly, the present invention describes a nucleic acid sequence and an amino acid sequence for a novel human EDG-6 receptor homologue.

BACKGROUND OF THE INVENTION

10 The family of *edg* (endothelial differentiation gene) receptors are commonly grouped with orphan receptors because their endogenous ligands are not known (for example see Hla, T. and Maciag, T. (1990) J. Biol. Chem. 265:9308-13; US patent 5,585,476). Recently, however, lysophosphatidic acid (LPA) has been demonstrated to be the endogenous
15 ligand for the *edg*-2 receptor (Hecht et al. (1996) J. Cell. Biol. 135: 1071-1083; An et al. (1997) Biochem. Biophys. Res. Comm. 213: 619-622).

 The *edg* family of receptors are seven transmembrane G protein coupled receptors (T7Gs). T7Gs are so named because of their seven hydrophobic domains which span the plasma membrane and form a bundle of antiparallel α helices. These transmembrane
20 segments (TMS) are designated by roman numerals I-VII and account for structural and functional features of the receptor. In most cases, the bundle of helices forms a binding pocket; however, when the binding site must accommodate more bulky molecules, the extracellular N-terminal segment or one or more of the three extracellular loops participate in
25 binding and in subsequent induction of conformational change in intracellular portions of the receptor. The activated receptor, in turn, interacts with an intracellular G-protein complex which mediates further intracellular signaling activities generally the production of second messengers such as cyclic AMP (cAMP), phospholipase C, inositol triphosphate or ion channel proteins.

 T7G receptors are expressed and activated during numerous developmental and
30 disease processes. Identification of a novel T7G receptor provides the opportunity to diagnose or intervene in such processes, and the receptor can be used in screening assays to identify physiological or pharmaceutical molecules which trigger, prolong or inhibit its activity.

SUMMARY OF THE INVENTION

The invention provides a unique nucleotide sequence which encodes a novel human
5 EDG-6 receptor homologue (HEDG). Herein, the nucleotide sequence encoding HEDG is
designated hedg. Thus, the invention provides an isolated nucleic acid molecule wherein the
nucleic acid molecule encodes a polypeptide having an amino acid sequence as shown in
SEQ. ID NO:2.

In another embodiment, the invention provides an isolated nucleic acid molecule
10 having a nucleotide sequence as shown in SEQ. ID NO:1.

In yet another embodiment, the invention provides a nucleic acid molecule which is
anti-sense to the molecules indicated above.

In a further embodiment, the invention provides for expression vectors, probes and
DNA constructs based on the polynucleotides mentioned above.

15 In another embodiment, the invention provides for a purified polypeptide having the
amino acid sequence as shown in SEQ. ID NO:2.

The invention also provides for antibodies specific to the above polypeptide.

In another embodiment, the invention provides for methods of purifying and assaying
polypeptides as indicated above.

20 In a further embodiment, the invention provides for transgenic animals which include
the nucleotide sequence of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

25 Figures 1A and 1B shows the alignment of the nucleic acid sequence (coding region
of SEQ. ID NO: 1) and amino acid sequence (SEQ. ID NO:2) for HEDG.

Figure 2 displays the nucleic acid sequence (SEQ. ID NO:3) of a cDNA encoding
HEDG.

30 DETAILED DESCRIPTION OF THE INVENTION

As used herein and designated by the upper case abbreviation, HEDG, refers to an
EDG-6 receptor homologue in either naturally occurring or synthetic form and active
fragments thereof which have the amino acid sequence of SEQ. ID NO:2. In one

embodiment, the polypeptide HEDG is encoded by mRNAs transcribed from the cDNA, as designated by the lower case abbreviation, *hedg*, of SEQ. ID NO:1.

The novel human EDG-6 receptor homologue, HEDG, was cloned and isolated from a human kidney proximal tubule cDNA library. It shows 52.9% identity to human *edg-2* (WO 97/00952).

An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single - or double - stranded nucleic acids or be chemically synthesized. They are useful in detecting the presence of identical or similar sequences.

A "portion" or "fragment" of a polynucleotide or nucleic acid comprises all or any part of the nucleotide sequence having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb which can be used as a probe. Such probes may be labeled with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. After optimizing reaction conditions to eliminate false positives, nucleic acid probes may be used in Southern, Northern or in situ hybridizations to determine whether DNA or RNA encoding HEDG is present in a cell type, tissue, or organ.

"Reporter" molecules are those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with, establish the presence of, and may allow quantification of a particular nucleotide or amino acid sequence.

"Recombinant nucleotide variants" encoding HEDG may be synthesized by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce specific restriction sites or codon usage-specific mutations, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic host system, respectively.

"Chimeric" molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one (or more than one) of the following

HEDG characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

"Active" refers to those forms, fragments, or domains of any HEDG polypeptide which retain the biological and/or antigenic activities of any naturally occurring HEDG.

5 "Naturally occurring HEDG" refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications including, but not limited to, alternative promoter usage, alternative splicing, alternative polyadenylation and RNA editing as well, as acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

10 "Derivative" refers to those polypeptides which have been chemically modified by such techniques as ubiquitination, labeling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.

15 "Recombinant polypeptide variant" refers to any polypeptide which differs from naturally occurring HEDG by amino acid insertions, deletions and/or substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest may be found by comparing the sequence of HEDG with that of related polypeptides and minimizing the number of amino acid sequence changes made in highly conserved regions. Variants in
20 which certain functional properties of HEDG are inactivated (i.e. signal transduction) may nonetheless retain other functional properties (e.g. ligand binding).

Amino acid "substitutions" are conservative in nature when they result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a
25 threonine with a serine.

"Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the hedg sequence using recombinant DNA techniques.

30 A "signal or leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides

of the present invention or provided from heterologous sources by recombinant DNA techniques.

5 An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. It may be functionally equivalent to and the same length as (or considerably shorter than) a "fragment", "portion", or "segment" of a polypeptide. Such sequences comprise a stretch of amino acid residues of at least about 5 amino acids and often about 17 or more amino acids, typically at least about 9 to 13 amino acids, and of sufficient length to display biological and/or antigenic activity.

10 A "chimeric" recombinant HEDG polypeptide refers to any polypeptide consisting of at least about 5 amino acids and often about 9 to 15 amino acids. Typically, such chimeric recombinants consist of 16 or more amino acids of the HEDG sequence covalently linked or expressed as a fusion protein with portions of one or more different, naturally-occurring or artificially created polypeptide sequences. Chimeric HEDG polypeptides are designed to alter the physical, biochemical, or functional properties of HEDG.

15 "Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

"Standard" expression is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

"Animal" as used herein may be defined to include human, domestic (cats dogs, etc.), agricultural (cows, horses, sheep, etc.) or test species (mouse, rat, rabbit, etc.).

25 The present invention provides a nucleotide sequence uniquely identifying a novel seven transmembrane receptor (T7G), human EDG-6 or HEDG. Based on the homology of HEDG to edg-2 it is likely that HEDG binds a ligand of the same chemical class. Edg-2 specifically binds lysophosphatidic acid (LPA) which is a phospholipid. Phospholipids have been demonstrated to be important regulators cell activity, including mitogenesis (Xu et al. (1995) J. Cell. Physiol., 163: 441-450) and apoptosis, cell adhesion and regulation of gene expression. Specifically, for example, LPA elicits growth factor-like effects on cell proliferation (Moolenaar (1996) J. Biol. Chem, 270: 12949-12952) and cell migration (Imamura et al. (1993) Biochem. Biophys. Res. Comm., 193: 497-503). It has also been

suggested that LPA plays a role in wound healing and regeneration (Tigyi et al. (1992) J. Biol. Chem., 267: 21360-21367). Further, considerable circumstantial evidence indicates that phospholipids may be involved in various disease states including cancer (Imamura et al., (1993) Biochem. Biophys. Res. Comm., 193: 497-503); diseases having an inflammatory component (Fourcade et al. (1995), Cell, 80(6): 919-927, including adult respiratory distress, neurodegeneration (Jalink et al. (1993) Cell Growth Differ., 4: 247-255), rheumatoid arthritis (Natarajan et al. (1995) J. Lipid Res., 36(9): 2005-2016), psoriasis and inflammatory bowel disease. Thus, the ligand for HEDG is likely to be a biologically important regulator of cell activity, and therefore aberrant expression of HEDG is likely to be associated with chronic or acute disease states. Further, modulators of HEDG activity are likely to be useful in treatment or prevention of such disease states.

HEDG ligands are likely to be found among the phospholipid class of compounds. Therefore, preferably phospholipid molecules should be screened to identify HEDG ligands. More preferably, lysophospholipids should be screened. Even more preferably, lysoglycerophospholipids should be screened. Most preferably, lysophosphatidic acid (LPA), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), lyso-platelet activating factor (lyso-PAF) and phosphatidic acid should be screened. Further, LPA has now been confirmed as a ligand and agonist for HEDG.

A diagnostic test for excessive expression of HEDG can accelerate diagnosis and proper treatment of abnormal conditions caused by viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma, leukemia or carcinoma; or other conditions which activate the genes of lymphoid or neuronal tissues.

The nucleotide sequences encoding HEDG (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of HEDG, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding HEDG disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology

techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of HEDG-encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring HEDG. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring hedg, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode HEDG, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring hedg under stringent conditions, it may be advantageous to produce nucleotide sequences encoding HEDG or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HEDG and/or its derivatives without altering the encoded aa (amino acid) sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

Nucleotide sequences encoding HEDG may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY; or Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York City). Useful nucleotide sequences for joining to hedg include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for hedg-specific hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding HEDG. Such probes may also be used for the detection of similar T7G encoding sequences and should preferably contain at least 40% nucleotide identity to hedg sequence. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ. ID NO:1 or from genomic sequences including promoter, enhancers or introns of the native gene. Hybridization probes may be labeled by a variety of reporter molecules using techniques well known in the art.

It will be recognized that many deletional or mutational analogs of nucleic acid sequences for HEDG will be effective hybridization probes for HEDG nucleic acid. Accordingly, the invention relates to nucleic acid sequences that hybridize with such HEDG encoding nucleic acid sequences under stringent conditions.

"Stringent conditions" refers to conditions that allow for the hybridization of substantially related nucleic acid sequences. For instance, such conditions will generally allow hybridization of a sequence with at least about 85% sequence identity, preferably with at least about 90% sequence identity, more preferably with at least about 95% sequence identity. Such hybridization conditions are described by Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1989. Hybridization conditions and probes can be adjusted in well-characterized ways to achieve selective hybridization of human-derived probes.

Nucleic acid molecules that will hybridize to HEDG encoding nucleic acid under stringent conditions can be identified functionally, using methods outlined above, or by using for example the hybridization rules reviewed in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1989.

Without limitation, examples of the uses for hybridization probes include: histochemical uses such as identifying tissues that express HEDG; measuring mRNA levels, for instance to identify a sample's tissue type or to identify cells that express abnormal levels of HEDG; and detecting polymorphisms in the HEDG. RNA hybridization procedures are described in Maniatis et al. *Molecular Cloning, a Laboratory Manual* (Cold Spring Harbor Press, 1989).

PCR as described US Patent No's. 4,683,195; 4,800,195; and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes

HEDG. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of hedg in specific tissues or diagnostic use. The same two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may
5 be employed under less stringent conditions for identification of closely related DNA's or RNA's.

Rules for designing polymerase chain reaction (PCR) primers are now established, as reviewed by PCR Protocols, Cold Spring Harbor Press, 1991. Degenerate primers, i.e., preparations of primers that are heterogeneous at given sequence locations, can be designed
10 to amplify nucleic acid sequences that are highly homologous to, but not identical to hedg. Strategies are now available that allow for only one of the primers to be required for specifically hybridizing with a known sequence. See, Froman et al., Proc. Natl. Acad. Sci. USA 85: 8998, 1988 and Loh et al., Science 243: 217, 1989. For example, appropriate nucleic acid primers can be ligated to the nucleic acid sought to be amplified to provide the
15 hybridization partner for one of the primers. In this way, only one of the primers need be based on the sequence of the nucleic acid sought to be amplified.

PCR methods of amplifying nucleic acid will utilize at least two primers. One of these primers will be capable of hybridizing to a first strand of the nucleic acid to be amplified and of priming enzyme-driven nucleic acid synthesis in a first direction. The other
20 will be capable of hybridizing the reciprocal sequence of the first strand (if the sequence to be amplified is single stranded, this sequence will initially be hypothetical, but will be synthesized in the first amplification cycle) and of priming nucleic acid synthesis from that strand in the direction opposite the first direction and towards the site of hybridization for the first primer. Conditions for conducting such amplifications, particularly under preferred
25 stringent hybridization conditions, are well known. See, for example, PCR Protocols, Cold Spring Harbor Press, 1991.

Other means of producing specific hybridization probes for hedg include the cloning of nucleic acid sequences encoding HEDG or HEDG derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available
30 and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA vectors and their respective host cells using techniques which are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

The nucleotide sequence for *hedg* can be used in an assay to detect inflammation or disease associated with abnormal levels of *HEDG* expression. The cDNA can be labeled by methods known in the art, added to a fluid, cell or tissue sample from a patient, and incubated under hybridizing conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a reporter molecule. After the compatible fluid is rinsed off, the reporter molecule is quantitated and compared with a standard as previously defined.

The nucleotide sequence for *hedg* can be used to construct hybridization probes for mapping the native gene. The gene may be mapped to a particular chromosome or to a specific region of a chromosome using well known mapping techniques. These techniques include in situ hybridization of chromosomal spreads (Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York City), flow-sorted chromosomal preparations, or artificial chromosome constructions such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. Examples of genetic map data can be found in the yearly genome issue of Science (e.g. 1994, 265:1981f). Often locating a gene on the chromosome of another mammalian species may reveal associated markers which can be used to help identify the analogous human chromosome.

New nucleotide sequences can be assigned to chromosomal subregions by physical mapping. The mapping of new genes or nucleotide sequences provide useful landmarks for investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely

localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti et al (1988) Nature 336:577-580), any sequences mapping to that area may represent or reveal genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in gene sequence between normal and carrier or affected individuals.

Nucleotide sequences encoding hedg may be used to produce a purified oligo - or polypeptide using well known methods of recombinant DNA technology. Goeddel (1990, Gene Expression Technology, Methods and Enzymology, Vol. 185, Academic Press, San Diego CA) is one among many publications which teach expression of an isolated nucleotide sequence. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

Cells transformed with DNA encoding HEDG may be cultured under conditions suitable for the expression of T7Gs, their extracellular, transmembrane or intracellular domains and recovery of such peptides from cell culture. HEDG (or any of its domains) produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps vary with the production process and the particular protein produced. Often an oligopeptide can be produced from a chimeric nucleotide sequence. This is accomplished by ligating the nucleotides from hedg or a desired portion of the polypeptide to a nucleic acid sequence encoding a polypeptide domain which will facilitate protein purification (Kroll D.J. et. al. (1993) DNA Cell Biol. 12:441-53). Chimeric receptors are useful in the purification of recombinant HEDG polypeptides, detection of interaction of recombinantly expressed HEDG receptors with ligands, and investigation of intracellular trafficking, signal transduction and interaction of HEDG with other intracellular proteins.

In addition to recombinant production, fragments of HEDG may be produced by direct peptide synthesis using solid-phase techniques (e.g. Stewart et. al. (1969) Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco CA; Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Automated synthesis may be achieved, for example, using Applied

Biosystems 431A Peptide Synthesizer (Foster City, CA) in accordance with the instructions provided by the manufacturer. Additionally, a particular portion of HEDG may be mutated during direct synthesis and combined with other parts of the peptide using chemical methods.

HEDG for antibody induction does not require biological activity: however, the protein must be antigenic. Peptides used to induce specific antibodies may have an aa sequence consisting of at least five amino acids (aa), preferably at least 10 aa. They should mimic a portion of the aa sequence of the protein and may contain the entire aa sequence of a small naturally occurring molecule such as HEDG. An antigenic portion of HEDG may be fused to another protein such as keyhole limpet hemocyanin, and the chimeric molecule used for antibody production.

Antibodies specific for HEDG may be produced by inoculation of an appropriate animal with the polypeptide or an antigenic fragment. An antibody is specific for HEDG if it is produced against an epitope of the polypeptide and binds to at least part of the natural or recombinant protein. Antibody production includes not only the stimulation of an immune response by injection into animals, but also analogous processes such as the production of synthetic antibodies, the screening of recombinant immunoglobulin libraries for specific-binding molecules (e.g. Orlandi R. et. al. (1989) PNAS 86:3833-3837, or Huse W.D. et. al. (1989) Science 256:1275-1281) or the in vitro stimulation of lymphocyte populations. Current technology (Winter G. and Milstein C. (1991) Nature 349:293-299) provides a number of highly specific binding reagents based on the principles of antibody formation. These techniques may be adapted to produce molecules which specifically bind HEDGs.

An additional embodiment of the subject invention is the use of HEDG specific antibodies, inhibitors, receptors or their analogs as bioactive agents to treat inflammation or disease including, but not limited to viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid or neuronal tissues.

Bioactive compositions comprising agonists, antagonists, receptors or inhibitors of HEDG may be administered in a suitable therapeutic dose determined by any of several methodologies including clinical studies on mammalian species to determine maximal tolerable dose and on normal human subjects to determine safe dose. Additionally, the bioactive agent may be complexed with a variety of well established compounds or compositions which enhance stability or pharmacological properties such as half-life. It is

contemplated that the therapeutic, bioactive composition may be delivered by intravenous infusion into the bloodstream or any other effective means which could be used for treating problems involving excessive lymphocyte and leukocyte trafficking.

Rheumatoid arthritis is currently evaluated on the basis of swelling, response to
5 NSAIDs, x-rays, etc. HEDG is most likely expressed on the surface of the fibroblasts, T and B lymphocytes, monocytemacrophages, or mast cells which comprise the cells of the inflamed synovium. Once adequate standards are established, an assay for the abnormal expression of HEDG is a viable diagnostic tool for assessing the extent that RA has progressed. The expression of HEDG in a sustained inflammatory response makes it a
10 valuable therapeutic target for screening drug libraries. Inhibitors of HEDG are useful for controlling signal transduction and signaling cascades in cells of the rheumatoid synovium.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

15

EXAMPLES**EXAMPLE 1**5 Isolation of human *edg-6* cDNAPCR amplification of *edg-6* cDNA from a human kidney proximal tubule cDNA library.

10 PCR reactions were conducted using EDG6-F1 or EDG6-R1 primers vs. primers derived from the pcDNA3 expression vector (Invitrogen catalog no. V790-20) in which this human kidney proximal tubule cDNA library was constructed (ATCC 87306).

EDG6-F1 5'-GGTGGTACTGCTCCTGGATGGTTTAG-3' (SEQ. ID NO:4)

EDG6-R1 5'-CGGAGGCACGCGCAGCAGAGAAGA-3' (SEQ. ID NO:5)

15 830F: [5'-TAGAGAACCCACTGCTTAC-3'] (SEQ. ID NO:6)

1186R:[5'-CCCAGAATAGAATGACACC-3'] (SEQ. ID NO:7)

20 One PCR reaction was done with EDG6-F1 vs. 1186R primers (representing the 3' end of *edg-6* cDNA clones), and another was done with 830F vs. EDG6-R1 primers (representing the 5' end of *edg-6* cDNA clones). Each 40 µl reaction contained the following reagents:

26.4 µl water

5.6 µl 2.5 mM dNTP mix

25 4 µl 10x ExpandTM Buffer 1 (Boehringer Mannheim Cat. No. 1681-842)

1.2 µl 10 µM EDG6-specific primer

1.2 µl 10 µM vector primer

0.6 µl Expand PCR enzyme (0.4 units)

1 µl diluted ATCC 87306 cDNA library stock (≥1 library equivalent/µl)

30

PCR Conditions:

Incubate: 94°C for 2 min

30 cycles: 92°C for 30 sec

55°C for 30 sec
 68°C for 3 min
 Incubate: 68°C for 8 min
 Hold: 4°C

5

The results showed 2 bands from the 3'-end cDNA reaction (EDG6-F1/1186R). The predominant band was 1.0 kb in length (designated 3'-2), while a fainter 1.6 kb band was also seen (3'-1). From the 5'-end reaction (830F/EDG6-R1) at least 8 bands were seen, ranging from about 1.7 kb to less than 500 bp. These bands were designated 5'-1, 5'-2, 5'-3, 5'-4, 5'-5, 5'-6, 5'-7 and 5'-8, in order from largest to smallest sized PCR products.

10

Each band was tip-eluted from the gel by stabbing the band with a fresh yellow Pipetman tip, which was then rinsed into 50 µl of TE, pH 8. Both 3'-1 and 3'-2 were picked separately, along with the eight 5' bands. The 50 µl solutions were then used as a stock from which re-amplifications were done using the same primers as in the original reaction, as follows:

15

12.7 µl water
 2.8 µl 2.5 mM dNTP mix
 2 µl 10x Expand™ Buffer 1
 0.6 µl 10 µM EDG6-specific primer
 0.6 µl 10 µM vector primer
 0.3 µl Expand PCR enzyme (0.4 units)
 1 µl tip-eluted DNA stock

20

25 PCR Conditions:

Incubate: 94°C for 2 min
 30 cycles: 92°C for 30 sec
 55°C for 30 sec
 68°C for 3 min
 Incubate: 68°C for 8 min
 Hold: 4°C

30

Sequencing was carried out using Applied Biosystems Inc. sequencing kit (catalog no. 402078). Sequencing of the re-amplified products determined that only three of the eight 5' PCR products (5'-4, 5'-5 and 5'-8) and one of the two 3' PCR products (3'-2) matched the
 5 edg-6 cDNA. This analysis also suggested that the longest 5' PCR product, 5'-4, contained the translation initiation codon and complete 5' portion of edg-6 coding sequence. In addition, the one 3' PCR product, 3'-2, contained the complete 3' portion of edg-6 coding sequence, including an extended 3'-untranslated region and 34 bp poly(A) tail, characteristic of eukaryotic mRNAs.

10

Full-length cloning of the human edg-6 cDNA into pcDNA3 vector.

Extension PCR (cycles without primers) was used to join the overlapping ~1.2 kb 5'-4 fragment and 1.0 kb 3'-2 fragment as follows:

Extension PCR :

15	12.2 µl	water
	2.8 µl	2.5 mM dNTP mix
	2 µl	10x Expand™ Buffer 1
	1 µl	edg-6 5'-4 PCR product
	1 µl	edg-6 3'-2 PCR product
20	1 µl	Expand PCR enzyme (3.5 units)

PCR Conditions:

	Incubate	94°C for 2 min
	10 cycles:	92°C for 1 min
25		65°C for 2 min
		68°C for 3 min
	Incubate:	68°C for 5 min
	Hold:	4°C

30 The following mix was then added:

56.3 µl water

- 11.2 µl 2.5 mM dNTP mix
8 µl 10x Expand™ Buffer 1
1.5 µl 10 µM 830F primer
1.5 µl 10 µM 1186R primer
5 1.5 µl Expand PCR enzyme (3.5 units/µl)

PCR Conditions:

- Incubate 94°C for 2 min
30 cycles: 92°C for 30 sec
10 65°C for 30 sec
68°C for 3 min
Incubate: 68°C for 8 min
Hold: 4°C

- 15 After gel electrophoresis of the PCR products, a weak DNA band of about 2.2 kb was seen.
Re-amplification was performed at a lower annealing temperature using 5ul of this PCR material in the following PCR reaction:

Re-amplification PCR:

- 20 63.5 µl water
14 µl 2.5 mM dNTP mix
10 µl 10x Expand™ Buffer 1
3 µl 10 µM 830F primer
3 µl 10 µM 1186R primer
25 1.5 µl Expand PCR enzyme (3.5 units/µl)
5 µl DNA from previous PCR reaction

PCR Conditions:

- Incubate 94°C for 2 min
30 30 cycles: 92°C for 30 sec
50°C for 30 sec

68°C for 3 min
Incubate: 68°C for 8 min
Hold: 4°C

- 5 On gel electrophoresis, an intense PCR product was seen at 2.2 kb. This product was gel purified from 20 µl of the PCR reaction, by cutting the appropriate band from the gel and recovering the DNA with a Qiaquick gel extraction kit from Qiagen Inc. (Cat no. 28706) in 25 µl of 10 mM Tris (pH 8.5).

- 10 Restriction digest of PCR sample with KpnI and XhoI:

A double digest was performed on 5 µl of the purified re-amplified PCR reaction as follows:

- 5 µl Re-amplified, gel-purified PCR DNA
5 µl 10X NEBuffer 2 (New England Biolabs [NEB])
15 1 µl KpnI restriction endonuclease (10 units; NEB, Cat #142S)
1 µl XhoI restriction endonuclease (20 units; NEB, Cat #146S)
5 µl 10X Acetylated BSA stock (NEB)
33 µl water

- 20 The restriction digest was incubated for 1 hour in a 37°C water block heater. The reaction products were run on a gel, the ~2 kb DNA band was cut out and purified from the gel in 10 µl of 10 mM Tris (pH 8.5).

Preparation of pcDNA3 cloning vector with KpnI and XhoI:

- 25 4 µl pcDNA3 plasmid DNA containing a 1.8 kb cDNA insert
10 µl 10X NEBuffer 2 (NEB)
3 µl KpnI restriction endonuclease (NEB: 1:10 dilution; 3 units)
3 µl XhoI restriction endonuclease (NEB: 1:20 dilution; 3 units)
10 µl 10X Acetylated BSA stock (NEB)
30 64 µl water

The vector DNA was digested for 1 hour at 37°C. Then, 3 units more of each enzyme was added and the tubes were incubated for a further 2 hr at 37°C. The digest was run on a gel, and the vector band without cDNA insert was cut out and purified using GeneCleanII kit (BIO 101) and eluted in 40 µl of 10 mM Tris (pH 8.5).

5

The double-digested, gel-purified PCR DNA was ligated into the prepared pcDNA3 plasmid vector using T4 DNA ligase kit (NEB, Cat #202CS) and transformed into Epicurean Coli XL-2 Blue MRF' Ultracompetent cells (Stratagene, Cat #200150). The transformation was plated onto 2xYT/Ampicillin plates and single colonies were picked. DNA mini-preps were made using QIAGEN QIA-Prep 8 mini-prep kit (Cat #27144) and clones with appropriate inserts were identified by sequencing, carried out with the in-house ABI automated sequencing system. From this analysis, a full length clone designated pC3-hEdg6 was chosen for complete sequence determination of the cDNA insert.

10

15 An open reading frame of 1053 bp constitutes the coding region of human edg-6. This coding region starts with a methionine codon at nt 91 (figure 1, SEQ ID NO:1), preceded by an in-frame translation initiation codon (TGA) at nt 76-78. Translation is terminated by a stop codon at nt 1144.

20 The edg-6 open reading frame of the pC3-hEdg6 clone predicts a 351 amino acid polypeptide with many typical features of a G protein-coupled receptor (GPCR). These include:

1. A hydropathy profile consistent with the 7 transmembrane structure of GPCRs:

- N-terminal extracellular domain: 1-33

25

- Transmembrane region 1 (TM-1) : 33-58

- Intracellular loop-1 (IL-1) :59-65

- TM-2: 66-94

- Extracellular loop-1 (EL-1) : 95-108

- TM-3: 109-127

30

- IL-2:128-146

- TM-4: 147-172

- EL-2: 173-188

- TM-5: 189-209
- IL-3:210-241
- TM-6: 242-263
- EL-3: 264-278
- 5 • TM-7: 279-299

2. C-terminal cytoplasmic domain: 300-351

Potential N-glycosylation sites in the extracellular N-terminal domain, residues 10 and 18

- 10 3. Potential N-myristoylation site at residue 331

Potential protein kinase C phosphorylation sites at residues 59, 305 and 334

The amino acid sequence of human edg-6 (Figure 1, SEQ ID NO:2) also shows very good conservation with other members of the edg subfamily of GPCRs. The pair-wise percent
15 identity is presented in the Table 1 below:

Table 1 Percent identity and percent similarity at the amino acid level of edg family to the human edg-6 receptor

Gene	Percent Identity	Percent Similarity
Edg-1 (Human)	33.7	56.0
Edg-2 (Human)	52.9	71.7
Edg-3 (Human)	33.9	56.5
H218 (Edg-4: Rat)	35.9	56.6

EXAMPLE 2

Homology Searching of cDNA Clones and Deduced Proteins

- 25 A FASTA search (GCG, FASTA version 3.0) against daily-updated in-house databases comprised of Genbank, EMBL, dbEST, the HTG, GSS and STS genomic sequencing databases revealed several sequence related to human edg-6. First, in addition to the original EST (T02954) found by database mining, 1 additional EST (Genbank W60555) closely

matched the edg-6 sequence (98.4% identity in a 386 nt overlap from nt 1078-1463). Second, the murine LPA receptor, edg-2, was the highest-scoring full-length cDNA sequence found from the combined Genbank/EMBL databases (Genbank MMU70622: 62.8% identity in 980 nt overlap from nt 106-1073). A lower degree of sequence identity was seen with the edg-1 orphan receptor (Genbank HUMEDG: 55.0% identity in 767 nt overlap from nt 277-1026).

EXAMPLE 3

Antisense analysis

Knowledge of the correct, complete cDNA sequence of HEDG enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of hedg are used either in vitro or in vivo to inhibit expression of the mRNA. Such technology is now well known in the art, and antisense molecules can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (e.g., lethality, loss of differentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes. Similarly, inhibition is achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing.

EXAMPLE 4

Expression of HEDG

Expression of hedg is accomplished by sub-cloning the cDNAs into appropriate expression vectors and transfecting the vectors into analogous expression hosts for example E.Coli. In a particular case, the vector is engineered such that it contains a promoter for β -galactosidase, upstream of the cloning site, followed by sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is

an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

Induction of the isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein corresponding to the first seven residues of β -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA will lie in the correct frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

The *hedg* cDNA is shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as Saccharomyces cerevisiae, and bacteria such as E. coli.

For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation in bacteria and a selectable marker such as the β -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced HEDG are recovered from the conditioned medium and analyzed using chromatographic methods known in the art. For example, HEDG can be expressibly cloned into the expression vector pcDNA3, as exemplified herein. This product can be used to transform, for example, HEK293 or COS by methodology standard in the art. Specifically, for example, using Lipofectamine (Gibco BRL catalog no. 18324-020) mediated gene transfer.

EXAMPLE 5

Isolation of Recombinant HEDG

HEDG is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle WA). The inclusion of a cleaveable linker sequence such as Factor XA or enterokinase (Invitrogen) between the purification domain and the HEDG sequence is useful to facilitate expression of HEDG.

EXAMPLE 6

Testing of Chimeric T7Gs

Functional chimeric T7Gs are constructed by combining the extracellular receptive sequences of a new isoform with the transmembrane and intracellular segments of a known isoform for test purposes. This concept was demonstrated by Kobilka et al (1988, Science 240:1310-1316) who created a series of chimeric $\alpha 2$ - $\beta 2$ adrenergic receptors (AR) by inserting progressively greater amounts of $\alpha 2$ -AR transmembrane sequence into $\beta 2$ -AR. The

binding activity of known agonists changed as the molecule shifted from having more $\alpha 2$ than $\beta 2$ conformation, and intermediate constructs demonstrated mixed specificity. The specificity for binding antagonists, however, correlated with the source of the domain VII. The importance of T7G domain VII for ligand recognition was also found in chimeras
5 utilizing two yeast α -factor receptors and is significant because the yeast receptors are classified as miscellaneous receptors. Thus, functional role of specific domains appears to be preserved throughout the T7G family regardless of category.

In parallel fashion, internal segments or cytoplasmic domains from a particular isoform are exchanged with the analogous domains of a known T7G and used to identify the
10 structural determinants responsible for coupling the receptors to trimeric G-proteins (Dohlman et al (1991) Ann. Rev. Biochem. 60:653-88). A chimeric receptor in which domains V, VI, and the intracellular connecting loop from $\beta 2$ -AR were substituted into $\alpha 2$ -AR was shown to bind ligands with $\alpha 2$ -AR specificity, but to stimulate adenylate cyclase in the manner of $\beta 2$ -AR. This demonstrates that for adrenergic-type receptors, G-protein
15 recognition is present in domains V and VI and their connecting loop. The opposite situation was predicted and observed for a chimera in which the V- > VI loop from $\alpha 1$ -AR replaced the corresponding domain on $\beta 2$ -AR and the resulting receptor bound ligands with $\beta 2$ -AR specificity and activated G-protein-mediated phosphatidylinositol turnover in the $\alpha 1$ -AR manner. Finally, chimeras constructed from muscarinic receptors also demonstrated that V-
20 > VI loop is the major determinant for specificity of G-protein activity (Bolander FF, supra).

Chimeric or modified T7Gs containing substitutions in the extracellular and transmembrane regions have shown that these portions of the receptor determine ligand binding specificity. For example, two Ser residues conserved in domain V of all adrenergic and D catecholamine T7G receptors are necessary for potent agonist activity. These serines
25 are believed to form hydrogen bonds with the catechol moiety of the agonists within the T7G binding site. Similarly, an Asp residue present in domain III of all T7Gs which bind biogenic amines is believed to form an ion pair with the ligand amine group in the T7G binding site. Functional, cloned T7Gs are expressed in heterologous expression systems and their biological activity assessed (e.g. Marullo et al (1988) Proc. Natl. Acad. Sci. 85:7551-55; King
30 et al (1990) Science 250:121-23). One heterologous system introduces genes for a mammalian T7G and a mammalian G-protein into yeast cells. The T7G is shown to have

appropriate ligand specificity and affinity and to trigger appropriate biological activation, growth arrest, and morphological changes of the yeast cells.

An alternate procedure for testing chimeric receptors is based on the procedure utilizing the P_{2u} purinergic receptor (P_{2u}) as published by Erb et. al. (1993, Proc. Natl. Acad. Sci. 90:104411-53). Function is easily tested in cultured K562 human leukemia cells because these cells lack P_{2u} receptors. K562 cells are transfected with expression vectors containing either normal or chimeric P_{2u} and loaded with fura-a, fluorescent probe for Ca^{++} . Activation of properly assembled and functional P_{2u} receptors with extracellular UTP or ATP mobilizes intracellular Ca^{++} which reacts with fura-a and is measured spectrofluorometrically. As with the T7G receptors above, chimeric genes are created by combining sequences for extracellular receptive segments of any newly discovered T7G polypeptide with the nucleotides for the transmembrane and intracellular segments of the known P_{2u} molecule. Bathing the transfected K562 cells in microwells containing appropriate ligands triggers binding and fluorescent activity defining effectors of the T7G molecule. Once ligand and function are established, the P_{2u} system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

EXAMPLE 7

Production of HEDG Specific Antibodies

Two approaches are utilized to raise antibodies to HEDG, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of an appropriate HEDG domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions, as illustrated in Figure 1, SEQ ID NO:2, are synthesized and used in suitable immunization protocols to raise antibodies.

Analysis to select appropriate epitopes is described by Ausubel FM et al (supra). The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.

5 Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St. Louis MO) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). If necessary, a cysteine is introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are
10 immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for anti-peptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of
15 interest are detected by screening with labeled HEDG to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto CA) are coated during incubation with affinity purified, specific rabbit anti-mouse (or suitable antispecies Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA, washed and incubated with supernatants from hybridomas.
20 After washing the wells are incubated with labeled HEDG at 1 mg/ml. Supernatants with specific antibodies bind more labeled HEDG than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascetic fluid by affinity
25 chromatography on Protein A. Monoclonal antibodies with affinities of at least 10^8 M⁻¹, preferably 10^9 to 10^{10} or stronger, are typically made by standard procedures as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and in Goding (1986) Monoclonal Antibodies: Principles and Practice, Academic Press, New York City, both incorporated herein by reference.

30

EXAMPLE 8**Diagnostic Test Using HEDG Specific Antibodies**

Particular HEDG antibodies are useful for investigating signal transduction and the
5 diagnosis of infectious or hereditary conditions which are characterized by differences in the
amount or distribution of HEDG or downstream products of an active signaling cascade.

Diagnostic tests for HEDG include methods utilizing antibody and a label to detect
HEDG in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides
and antibodies of the present invention are used with or without modification. Frequently,
10 the polypeptides and antibodies are labeled by joining them, either covalently or non-
covalently, with a substance which provides for a detectable signal. A wide variety of labels
and conjugation techniques are known and have been reported extensively in both the
scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates,
cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents,
15 magnetic particles and the like. Patents teaching the use of such labels include US Patent
No's. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
Also, recombinant immunoglobulins may be produced as shown in US Patent No.4,816,567,
incorporated herein by reference.

A variety of protocols for measuring soluble or membrane-bound HEDG, using either
20 polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples
include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and
fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay
utilizing monoclonal antibodies reactive to two non-interfering epitopes on HEDG is
preferred, but a competitive binding assay may be employed. These assays are described,
25 among other places, in Maddox, DE et al (1983, J Exp. Med. 158:1211f).

EXAMPLE 9**Purification of Native HEDG Using Specific Antibodies**

30 Native or recombinant HEDG is purified by immunoaffinity chromatography using
antibodies specific for HEDG. In general, an immunoaffinity column is constructed by
covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation
with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB

Biotechnology, Piscataway NJ). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to
5 the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of HEDG by preparing a fraction from cells containing HEDG in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential
10 centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble HEDG containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

A soluble HEDG-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HEDG
15 (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/protein binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and HEDG is collected.

EXAMPLE 10**Drug Screening**

This invention is particularly useful for screening therapeutic compounds by using
5 HEDG or binding fragments thereof in any of a variety of drug screening techniques. As
HEDG is a G protein coupled receptor, any of the methods commonly used in the art may
potentially used to identify HEDG ligands. Alternatively, the polypeptide or fragment
employed in such a test is either free in solution, affixed to a solid support, borne on a cell
surface or located intracellularly. One method of drug screening utilizes eukaryotic or
10 prokaryotic host cells which are stably transformed with recombinant nucleic acids
expressing the polypeptide or fragment. Drugs are screened against such transformed cells in
competitive binding assays. Such cells, either in viable or fixed form, are used for standard
binding assays. One measures, for example, the formation of complexes between HEDG and
the agent being tested. Alternatively, one examines the diminution in complex formation
15 between HEDG and a ligand caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other
agents which affect signal transduction. These methods, well known in the art, comprise
contacting such an agent with HEDG polypeptide or a fragment thereof and assaying (i) for
the presence of a complex between the agent and the HEDG polypeptide or fragment, or (ii)
20 for the presence of a complex between the HEDG polypeptide or fragment and the cell. In
such competitive binding assays, the HEDG polypeptide or fragment is typically labeled.
After suitable incubation, free HEDG polypeptide or fragment is separated from that present
in bound form, and the amount of free or uncomplexed label is a measure of the ability of the
particular agent to bind to HEDG or to interfere with the HEDG and agent complex.

25 In another embodiment, the invention is suitable for screening potential drugs by
known methods of signal transduction assays for G protein coupled receptors. For example,
the activity of a G protein coupled receptor such as HEDG can be measured using any of a
variety of appropriate functional assays in which activation of the receptor results in an
observable change in the level of some second messenger system, such as adenylate cyclase,
30 guanylylcyclase, calcium mobilization, or inositol phospholipid hydrolysis. One such
method involves the following steps:

a) co-transfection into a suitable cell of a plasmid including a reporter gene (for
example, luciferase under the transcriptional control of SRE, serum response element) and an

expression plasmid for HEDG. SRE is known in the art as a common reporter for G protein coupled receptors which respond to mitogenic factors.

- b) expression of HEDG;
- c) pre-treatment of the transformed cell with serum starvation to reduce mitogenic signaling;
- d) application of LPA in serum free medium; and,
- e) after 5 hours, measuring luciferase activity.

This method relies on the activation of HEDG upon addition of LPA. Expression of the reporter gene, coding for luciferase, is induced by the mitogenic signal transduction resulting from the activation of HEDG by LPA. In this manner, other agonists of HEDG can be assayed. Therefore, with such a method, an increase in luciferase activity signals the presence of an agonist (i.e. LPA) for the subject receptor, while a decrease in luciferase activity signals the presence of an antagonist. Although luciferase is indicated as a preferred reporter in the above example, various other reporters (as discussed previously) can also be used.

EXAMPLE 11

Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, agonists, antagonists, or inhibitors. Any of these examples are used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo (e.g., Hodgson J. (1991) Bio/Technology 9:19-21, incorporated herein by reference).

In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design includes molecules which have improved activity or stability as shown by Braxton S.

and Wells J.A. (1992, Biochemistry 31:7796-7801) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda S.B. et. al. (1993 J Biochem. 113:742-46), incorporated herein by reference.

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.

By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the HEDG amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

EXAMPLE 12

Identification of Other Members of the Signal Transduction Complex

The inventive purified HEDG is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins. Radioactive labels are incorporated into a selected HEDG domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in HEDG with ¹²⁵I Bolton-Hunter reagent (Bolton, A.E. and Hunter, W.M. (1973) Biochem. J. 133: 529). This reagent has been used to label various molecules without concomitant loss of biological activity (Hebert C.A. et. al. (1991) J. Biol. Chem. 266:18989; McColl S. et. al. (1993) J. Immunol. 150:4550-4555).

Labeled HEDG is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound HEDG is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to HEDG. HEDG-complex is recovered from the column, and the HEDG-binding ligand disassociated and subjected to N-terminal protein sequencing. This as sequence is then used

to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

In an alternate method, antibodies are raised against HEDG, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the
5 binding of labeled HEDG. These monoclonal antibodies are then used therapeutically.

In yet a further embodiment, it is possible to identify other intracellular proteins that have an affinity for the cytoplasmic portion (i.e. the primary sequence) of HEDG. In this method, the subject primary sequence is isolated and subjected to any of the known methods for assaying protein interactions such as affinity columns, glass beads, or a two hybrid system
10 (cDNA Library Protocols; Cowell, I.G. and Austin C.A. (ed.), Methods in Molecular Biology, 69 (1996)).

EXAMPLE 13

Use and Administration of Antibodies, Inhibitors, or Antagonists

15 Antibodies, inhibitors, or antagonists of HEDG (or other treatments to limit signal transduction, LST) provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to
20 the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.

25 LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies
30 according to each specific situation. Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST. Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and

frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

5 Normal dosage amounts vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from
10 that to other cells such as vascular endothelial cells.

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger HEDG activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections; allergic responses; mechanical injury associated
15 with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid or neuronal tissues.

EXAMPLE 14

Autoimmune Disorders

20 Autoimmune disorders whereby antibodies are produced against HEDG can be expected to be associated with disease states. For example, for HEDG, such disorders can be expected to be associated with decreased muscle activity that presents symptoms much like myasthenia gravis, or to be associated with decreased pain perception. See, for an example of
25 a disease caused by autoantibodies to a molecule involved in neurotransmission (glutamic acid decarboxylase), Nathan et al., J. Neurosci. Res. 40: 134-137, 1995.

The presence of these antibodies can be measured by established immunological methods using protein sequences obtained from the nucleic acids described herein or the related glycine transporters reported elsewhere. See, for example, Kim et al., Mol.
30 Pharmacol., 45: 608-617, 1994 and Liu et al., J. Bio. Chem. 268: 22802-22808, 1992. Such immunological methods are described, for example, in Ausubel et al., Short Protocols in Molecular Biology, John Wiley & Sons, New York, 1992.

EXAMPLE 15**Production of Transgenic Animals**

Animal model systems which elucidate the physiological and behavioral roles of the HEDG receptor are produced by creating transgenic animals in which the activity of the HEDG receptor is either increased or decreased, or the amino acid sequence of the expressed HEDG receptor is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a HEDG receptor, by microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriate fertilized embryos in order to produce a transgenic animal or 2) Homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these HEDG receptor sequences. The technique of homologous recombination is well known in the art. It replaces the native gene with the inserted gene and so is useful for producing an animal that cannot express native HEDG receptors but does express, for example, an inserted mutant HEDG receptor, which has replaced the native HEDG receptor in the animal's genome by recombination, resulting in underexpression of the transporter. Microinjection adds genes to the genome, but does not remove them, and so is useful for producing an animal which expresses its own and added HEDG receptors, resulting in overexpression of the HEDG receptors.

One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their receptor is cesium chloride oviducts. The eggs are stored in an appropriate medium such as M2 medium. DNA or cDNA encoding a HEDG purified from a vector by methods well known in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the transgene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a piper puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse (a

mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only methods for inserting DNA into the egg cell, and is used here only for exemplary purposes.

5 All publications and patents mentioned in the above specification are herein incorporated by reference.

Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific
10 preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: MUNROE, Donald G.
VYAS, Tejal B.
- (ii) TITLE OF INVENTION: A HUMAN EDG-6 RECEPTOR HOMOLOG
- (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Nikaido, Marmelstein, Murray & Oram LLP
 - (B) STREET: 655 15th St., NW, Suite 330 - G Street Lobby
 - (C) CITY: Washington
 - (D) STATE: DC
 - (E) COUNTRY: USA
 - (F) ZIP: 20005-5701
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/861,747
 - (B) FILING DATE: 22-MAY-1997
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Jahns, Kristina M.
 - (B) REGISTRATION NUMBER: 41,092
 - (C) REFERENCE/DOCKET NUMBER: P8074-7003
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (202) 638-5000
 - (B) TELEFAX: (202) 638-4810

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1761 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCTCCCGCC GCAGTCGCCG GGCCATGGGC CTCGAGCCCG CCCC GAACCC CCGCGAGCCC	60
GCCTTGCTCTG CGGCGTGACT GGAGGCCAG ATGGTCATCA TGGGCCAGTG CTACTACAAC	120
GAGACCATCG GTTCTTCTA TAACAACAGT GGCAAAGAGC TCAGCTCCCA CTGGCGGCCC	180

AAGGATGTGG TCGTGGTGGC ACTGGGGCTG ACCGTCAGCG TGCTGGTGCT GCTGACCAAT	240
CTGCTGGTCA TAGCAGCCAT CGCCTCCAAC CGCCGCTTCC ACCAGCCCAT CTACTACCTG	300
CTCGGCAATC TGGCCGCGGC TGACCTCTTC GCGGGCGTGG CCTACCTCTT CCTCATGTTC	360
CACACTGGTC CCCGCACAGC CCGACTTTCA CTTGAGGGCT GGTTCCTGCG GCAGGGCTTG	420
CTGGACACAA GCCTCACTGC GTCGGTGGCC ACACTGCTGG CCATCGCCGT GGAACGGCAC	480
CGCAGTGTGA TGGCCGTACA GTTGACAGC CGCCTGCCCC GTGGCCGCGT GGTTCATGCTC	540
ATTGTGGGCG TGTGGGTGGC TGCCCTGGGC CTGGGGCTGT TGCTTGCCCA CTCCTGGCAC	600
TGCCTCTGTG CCCTGGACCG CTGCTCACGC ATGGCACCCC TGCTCAGCCG CTCCTATTTG	660
GCCGTCTGGG CTCTGTCGAG CCTGCTTGTC TTCCTGCTCA TGGTGGCTGT GTACACCCGC	720
ATTTTTTTTAT ACGTGCGGCG GCGAGTGCAG CGCATGGCAG AGCATGTCAG CTGCCACCCC	780
CGCTACCGAG AGACCACGCT CAGCCTGGTC AAGACTGTTG TCATCATCCT GGGGGCGTTC	840
GTGGTCTGCT GGACACCAGG CCAGGTGGTA CTGCTCCTGG ATGGTTTAGG CTGTGAGTCC	900
TGCAATGTCC TGGCTGTAGA AAAGTACTTC CTACTGTTGG CCGAGGCCAA CTCACTGGTC	960
AATGCTGCTG TGTACTCTTG CCGAGATGCT GAGATGCGCC GCACCTTCCG CCGCCTTCTC	1020
TGCTGCGCGT GCCTCCGCCA GCCCACCCGC GAGTCTGTCC ACTATACATC CTCTGCCCAG	1080
GGAGGTGCCA GCACTCGCAT CATGCTTCCC GAGAACGGCC ACCCACTGAT GGACTCCACC	1140
CTTTAGCTAC CTTGAACCTC AGCGGTACGC GGCAAGCAAC AAATCCACAG CCCCTGATGA	1200
CTTGTGGGTG CTCCTGGCTC AACCCAACCA ACAGGACTGA CTGACCGGCA GGACAAGGTC	1260
TGGCATGGCA CAGCACCCTC GCCAGGCCTC CCCAGGCACA CCACTCTGCC CAGGGGAATGG	1320
GGGCTTTGGG TCATCTCCCA CTGCCTGGGG GAGTCAGATG GGGTGCAGGA ATCTGGCTCT	1380
TCAGCCATCC CAGGTTTAGG GGGTTTGTA CAGACATTAT TCTGTTTTCA CTGCGTATCC	1440
TTGGTAAGCC CTGTGGACTG GTTCCTGCTG TGTGATGCTG AGGGTTTTAA GGTGGGGAGA	1500
GATAAGGGCT CTCTCGGGCC ATGCTACCCG GTATGACTGG GTAATGAGGA CAGACTGTGG	1560
ACACCCCATY TACCTGAGTC TGATTCTTTA GCAGCAGAGA CTGAGGGGTG CAGAGTGTGA	1620
GCTGGGAAAG GTTTGTGGCT CCTTGCAGCC TCCAGGGACT GGCCTGTCCC CGATAGAATT	1680
GAAGCAGTCC ACGGGGAGGG GATGATACAA GGAGTAAACC TTTCTTTACA CTCTGAGGTC	1740
TCCAAAACAT TTGTTGTTAT C	1761

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 351 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Val Ile Met Gly Gln Cys Tyr Tyr Asn Glu Thr Ile Gly Phe Phe
 1           5           10           15

Tyr Asn Asn Ser Gly Lys Glu Leu Ser Ser His Trp Arg Pro Lys Asp
      20           25           30

Val Val Val Val Ala Leu Gly Leu Thr Val Ser Val Leu Val Leu Leu
 35           40           45

Thr Asn Leu Leu Val Ile Ala Ala Ile Ala Ser Asn Arg Arg Phe His
 50           55           60

Gln Pro Ile Tyr Tyr Leu Leu Gly Asn Leu Ala Ala Ala Asp Leu Phe
 65           70           75           80

Ala Gly Val Ala Tyr Leu Phe Leu Met Phe His Thr Gly Pro Arg Thr
      85           90           95

Ala Arg Leu Ser Leu Glu Gly Trp Phe Leu Arg Gln Gly Leu Leu Asp
      100          105          110

Thr Ser Leu Thr Ala Ser Val Ala Thr Leu Leu Ala Ile Ala Val Glu
 115          120          125

Arg His Arg Ser Val Met Ala Val Gln Leu His Ser Arg Leu Pro Arg
 130          135          140

Gly Arg Val Val Met Leu Ile Val Gly Val Trp Val Ala Ala Leu Gly
 145          150          155          160

Leu Gly Leu Leu Pro Ala His Ser Trp His Cys Leu Cys Ala Leu Asp
      165          170          175

Arg Cys Ser Arg Met Ala Pro Leu Leu Ser Arg Ser Tyr Leu Ala Val
      180          185          190

Trp Ala Leu Ser Ser Leu Leu Val Phe Leu Leu Met Val Ala Val Tyr
 195          200          205

Thr Arg Ile Phe Leu Tyr Val Arg Arg Arg Val Gln Arg Met Ala Glu
 210          215          220

His Val Ser Cys His Pro Arg Tyr Arg Glu Thr Thr Leu Ser Leu Val
 225          230          235          240

Lys Thr Val Val Ile Ile Leu Gly Ala Phe Val Val Cys Trp Thr Pro
      245          250          255

Gly Gln Val Val Leu Leu Leu Asp Gly Leu Gly Cys Glu Ser Cys Asn
 260          265          270

Val Leu Ala Val Glu Lys Tyr Phe Leu Leu Leu Ala Glu Ala Asn Ser
 275          280          285

Leu Val Asn Ala Ala Val Tyr Ser Cys Arg Asp Ala Glu Met Arg Arg
 290          295          300

Thr Phe Arg Arg Leu Leu Cys Cys Ala Cys Leu Arg Gln Pro Thr Arg
 305          310          315          320

```


Glu	Ser	Val	His	Tyr	Thr	Ser	Ser	Ala	Gln	Gly	Gly	Ala	Ser	Thr	Arg
				325					330					335	
Ile	Met	Leu	Pro	Glu	Asn	Gly	His	Pro	Leu	Met	Asp	Ser	Thr	Leu	
			340					345					350		

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1889 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEO ID NO:3:

TTACGAATTA	ATACGATCAC	TATAGGGAGA	CCAAGCTTGG	TACCGAGCTC	GGATCCACTA	60
GTAACGGCCG	CCAGTGTGGG	GAATTCCGCT	CCCGCCGCAG	TCGCCGGGCC	ATGGGCCTCG	120
AGCCCGCCCC	GAACCCCCGC	GAGCCCGCCT	TGTCTGCGGC	GTGACTGGAG	GCCCAGATGG	180
TCATCATGGG	CCAGTGCTAC	TACAACGAGA	CCATCGGTTT	CTTCTATAAC	AACAGTGGCA	240
AAGAGCTCAG	CTCCCACTGG	CGGCCCAAGG	ATGTGGTCGT	GGTGGCACTG	GGGCTGACCG	300
TCAGCGTGCT	GGTGCTGCTG	ACCAATCTGC	TGGTCATAGC	AGCCATCGCC	TCCAACCGCC	360
GCTTCCACCA	GCCCATCTAC	TACCTGCTCG	GCAATCTGGC	CGCGGCTGAC	CTCTTCGCGG	420
GCGTGCCCTA	CCTCTTCCTC	ATGTTCCACA	CTGGTCCCCG	CACAGCCCGA	CTTTCACTTG	480
AGGGCTGGTT	CCTGCGGCAG	GGCTTGCTGG	ACACAAGCCT	CACTGCGTCG	GTGGCCACAC	540
TGCTGGCCAT	CGCCGTGGAA	CGGCACCGCA	GTGTGATGGC	CGTACAGTTG	CACAGCCGCC	600
TGCCCCGTGG	CCGCGTGGTC	ATGCTCATTG	TGGGCGTGTG	GGTGGCTGCC	CTGGGCCTGG	660
GGCTGTTGCC	TGCCCCTCC	TGGCACTGCC	TCTGTGCCCT	GGACCGCTGC	TCACGCATGG	720
CACCCCTGCT	CAGCCGCTCC	TATTTGGCCG	TCTGGGCTCT	GTCGAGCCTG	CTTGTCTTCC	780
TGCTCATGGT	GGCTGTGTAC	ACCCGCATTT	TTTTATACGT	GCGGCGGCCA	GTGCAGCGCA	840
TGGCAGAGCA	TGTCAGCTGC	CACCCCCGCT	ACCAGAGAC	CACGCTCAGC	CTGGTCAAGA	900
CTGTTGTTCAT	CATCCTGGGG	GCGTTCGTGG	TCTGCTGGAC	ACCAGGCCAG	GTGGTACTGC	960
TCCTGGATGG	TTTAGGCTGT	GAGTCCTGCA	ATGTCCTGGC	TGTAGAAAAG	TACTTCCTAC	1020
TGTTGGCCGA	GGCCAACTCA	CTGGTCAATG	CTGCTGTGTA	CTCTTGCCGA	GATGCTGAGA	1080
TGCGCCGCAC	CTTCCGCCGC	CTTCTCTGCT	GCGCGTGCCT	CCGCCAGCCC	ACCCGCGAGT	1140
CTGTCCACTA	TACATCCTCT	GCCCAGGGAG	GTGCCAGCAC	TCGCATCATG	CTTCCCGAGA	1200
ACGGCCACCC	ACTGATGGAC	TCCACCCTTT	AGCTACCTTG	AAC TTCAGCG	GTACGCGGCA	1260
AGCAACAAT	CCACAGCCCC	TGATGACTTG	TGGGTGCTCC	TGGCTCAACC	CAACCAACAG	1320

GACTGACTGA CCGGCAGGAC AAGGTCTGGC ATGGCACAGC ACCACTGCCA GGCTTCCCCA 1380
 GGCACACCAC TCTGCCCAGG GAATGGGGGC TTTGGGTCAT CTCCCCTGC CTGGGGGAGT 1440
 CAGATGGGGT GCAGGAATCT GGCTCTTCAG CCATCCCAGG TTTAGGGGGT TTGTAACAGA 1500
 CATTATTCTG TTTTCACTGC GTATCCTTGG TAAGCCCTGT GGACTGGTTC CTGCTGTGTG 1560
 ATGCTGAGGG TTTTAAGGTG GGGAGAGATA AGGGCTCTCT CGGGCCATGC TACCCGGTAT 1620
 GACTGGGTAA TGAGGACAGA CTGTGGACAC CCCATYTACC TGAGTCTGAT TCTTTAGCAG 1680
 CAGAGACTGA GGGGTGCAGA GTGTGAGCTG GGAAAGGTTT GTGGCTCCTT GCAGCCTCCA 1740
 GGGACTGGCC TGTCCCCGAT AGAATTGAAG CAGTCCACGG GGAGGGGATG ATACAAGGAG 1800
 TAAACCTTTC TTTACACTCT GAGGTCTCCA AAACATTTGT TGTATCAAA AAAAAAAAAA 1860
 AAAAAAAAAA AAAAAAAAAA AGCGGCCCGC 1889

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGTGGTACTG CTCCTGGATG GTTTAG 26

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CGGAGGCACG CGCAGCAGAG AAGA 24

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TAGAGAACCC ACTGCTTAC

19

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCCAGAATAG AATGACACC

19

**THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:**

1. An isolated nucleic acid molecule wherein said nucleic acid molecule encodes a polypeptide having an amino acid sequence as shown in SEQ. ID NO:2.
2. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid is DNA.
3. The isolated nucleic acid of claim 2 wherein said nucleic acid is selected from the group consisting of:
 - a) the nucleotide sequence as shown in SEQ. ID NO:1;
 - b) nucleotide sequences that hybridize to SEQ. ID NO:1 or to its complementary strand;
 - c) nucleotide sequences that differ from SEQ. ID NO:1 and from the nucleotide sequences of (b) in codon sequence due the degeneracy of the genetic code.
4. The isolated nucleic acid of claim 2 wherein said nucleic acid includes the nucleotide sequence as shown in SEQ. ID NO:1.
5. The isolated nucleic acid of claim 1 wherein said nucleic acid is RNA.
6. An isolated nucleic acid which is anti-sense to a nucleic acid as claimed in claim 1.
7. An isolated nucleic acid which is anti-sense to a nucleic acid as claimed in claim 3.
8. An isolated nucleic acid which is anti-sense to a nucleic acid as claimed in claim 4.
9. The isolated nucleic acid of claim 1 which is an RNA anti-sense sequence.
10. A DNA construct comprising the following operably linked elements:
 - a) a transcriptional promoter;
 - b) a DNA sequence including the nucleotide sequence as shown in SEQ. ID NO:1;and,
 - c) a transcriptional terminator.
11. The DNA construct of claim 10 wherein said DNA sequence encodes the polypeptide of SEQ. ID NO:2.
12. A recombinant expression vector suitable for transformation of a host cell comprising a nucleic acid as claimed in claim 1 and a regulatory sequence operatively linked to said nucleic acid.
13. A recombinant expression vector suitable for transformation of a host cell comprising a DNA molecule having a nucleotide sequence as shown in SEQ. ID NO:1 and a regulatory sequence operatively linked to said DNA molecule.

14. The recombinant expression vector of claim 13 wherein the DNA molecule is operatively linked to the regulatory sequence to allow expression of an RNA molecule which is anti-sense to a nucleotide sequence as shown in SEQ. ID NO:1.
15. A transformed cell including a recombinant expression vector as claimed in claim 12.
- 5 16. A transformed cell including a recombinant expression vector as claimed in claim 13.
17. A method for preparing an isolated protein having an amino acid sequence as shown in SEQ. ID NO:2 said method comprising culturing a transformed cell including a recombinant expression vector as claimed in claim 13 in a suitable medium until the protein is formed and isolating said protein.
- 10 18. The polypeptide expressed by the expression vector of claim 13.
19. pharmaceutical composition comprising the antisense molecule of claim 3 and a pharmaceutically acceptable carrier.
20. A probe comprising an oligonucleotide of the nucleic acid as shown in SEQ. ID NO:1 capable of specifically hybridizing with a gene which encodes a protein having an amino acid
- 15 sequence as shown in SEQ. ID NO:2 or allelic and species variants thereof.
21. An isolated polypeptide having the amino acid sequence as shown in SEQ. ID NO:2.
22. A purified polyclonal antibody specific for the amino acid sequence as shown in SEQ. ID NO:2.
23. The purified polyclonal antibody of claim 22 wherein said antibody is specific for an
- 20 extracellular epitope of the protein having the amino acid sequence as shown in SEQ. ID NO:2.
24. The purified polyclonal antibody of claim 22 wherein the antibody is labeled.
25. A monoclonal antibody specific for the amino acid sequence as shown in SEQ. ID NO:2.
- 25 26. The monoclonal antibody of claim 25 wherein said antibody is specific for an extracellular epitope of the protein having the amino acid sequence as shown in SEQ. ID NO:2.
27. The monoclonal antibody of claim 25 wherein the antibody is labeled.
28. The method for determining the presence of a protein having an amino acid sequence
- 30 as shown in SEQ. ID NO:2 in a biological sample, the method comprising the steps of:
 - a) incubating the sample with a monoclonal antibody or purified polyclonal antibody which specifically binds to an epitope of said protein under conditions sufficient for the formation of an immune complex; and,

b) determining the presence of said immune complex.

29. The method of claim 28 wherein the monoclonal or purified polyclonal antibody is labeled.

30. A method of purifying a protein having the amino acid sequence as shown in SEQ. ID NO:2, the method including an immunoaffinity chromatography process wherein a monoclonal antibody or a purified polyclonal antibody specific to an epitope of said protein is immobilized on the chromatography resin.

31. A method of screening a molecule which ligates to the protein having the amino acid sequence as shown in SEQ. ID NO:2 comprising a signal transduction assay.

10 32. The method of claim 31, wherein the protein is a G protein coupled receptor, the method comprising the following steps:

a) co-transfecting into a suitable cell of a plasmid including a reporter gene and an expression plasmid coding for said protein;

b) expressing said protein;

15 c) treating said cell with serum starvation to reduce mitogenic activity;

d) applying said molecule which ligates to said protein in a serum free medium; and,

e) measuring the activity of the reporter.

33. A transgenic animal expressing a first transgene coding for a protein having an amino acid sequence as shown in SEQ. ID NO:2.

20 34. The transgenic animal of claim 33 wherein said first transgene comprises a polynucleotide having a nucleotide sequence as shown in SEQ. ID NO:1.

35. A transgenic animal as claimed in claim 33 further including a second transgene coding for an inducible promoter for said first transgene.

25 36. A transgenic animal as claimed in claim 33 further including a second transgene coding for a tissue specific regulatory element for regulating the expression of said first transgene.

AMENDED CLAIMS

[received by the International Bureau on 6 November 1998 (06.11.98);
original claims 1-36 replaced by amended claims 1-22 (3 pages)].

- 5 1. An isolated nucleic acid molecule wherein the molecule is selected from the group consisting of :
- a) a molecule having a nucleic acid sequence as shown in SEQ. ID. NO: 1; and
 - b) hybridizing nucleic acid molecules that hybridize to a molecule having a nucleic acid sequence as shown in SEQ. ID NO:1 or to complementary strands thereof, said
- 10 hybridizing nucleic acid molecules having at least 40% homology with a molecule having a nucleic acid sequence as shown in SEQ. ID NO:1.
2. The molecule of claim 1 wherein said hybridizing nucleic acid molecule hybridizes to
- 15 SEQ. ID NO:1 under stringent conditions.
3. The molecule of claim 1 wherein said hybridizing nucleic acid molecule has at least 85% homology with a molecule having a nucleic acid sequence as shown in SEQ. ID NO:1.
4. The molecule of claim 1 wherein said hybridizing nucleic acid molecule has at least
- 20 90% homology with a molecule having a nucleic acid sequence as shown in SEQ. ID NO:1.
5. The molecule of claim 1 wherein said hybridizing nucleic acid molecule has at least 95% sequence identity with a molecule having a nucleic acid sequence as shown in SEQ. ID NO:1.
- 25
6. A DNA construct comprising the following operably linked elements:
- a) a transcriptional promoter;
 - b) a DNA sequence including the nucleotide sequence as claimed in claim 2; and,
 - c) a transcriptional terminator.
- 30
7. A recombinant expression vector suitable for transformation of a host cell comprising a nucleic acid as claimed in claim 2 and a regulatory sequence operatively linked to said nucleic acid.

8. A transformed cell including a recombinant expression vector as claimed in claim 7.
9. A method for preparing an isolated amino acid sequence as claimed in claim 2, said method comprising culturing a transformed cell as claimed in claim 8 in a suitable medium
5 until the protein is formed and isolating said protein.
10. The polypeptide expressed by the recombinant expression vector of claim 7.
11. A probe comprising an oligonucleotide of the nucleic acid as claimed in claim 2
10 capable of specifically hybridizing with a gene which encodes a protein having an amino acid sequence as shown in SEQ. ID. NO: 2 or allelic and species variants thereof.
12. A purified polyclonal antibody specific for the amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants thereof.
15
13. The purified polyclonal antibody of claim 12 wherein the antibody is specific for an extracellular epitope of the protein having the amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants thereof.
- 20 14. The purified polyclonal antibody of claim 12 wherein the antibody is labeled.
15. A monoclonal antibody specific for the amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants thereof.
- 25 16. The monoclonal antibody of claim 15 wherein said antibody is specific for an extracellular epitope of the protein having the amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants thereof.
- 30 17. The monoclonal antibody of claim 15 wherein the antibody is labeled.

18. The method for determining the presence of a protein having an amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants thereof in a biological sample, the method comprising the steps of:

- a) incubating the sample with amonoclonal antibody or purified polyclonal antibody which specifically binds to an epitope of said protein under conditions sufficient for the formation of an immune complex; and,
- b) determining the presence of said immune complex.

19. The method of claim 18 wherein the monoclonal or purified polyclonal antibody is labeled.

20. A method of purifying a protein having the amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants thereof, the method including an immunoaffinity chromatography process wherein a monoclonal antibody or a purified polyclonal antibody specific to an epitope of said protein is immobilized on the chromatography resin.

21. A method of screening a molecule which ligates to the protein having the amino acid sequence as shown in SEQ. ID. NO: 2 or allelic variants or fragments thereof comprising a signal transduction assay.

20

22. The method of claim 21, wherein the protein is a G protein coupled receptor, the method comprising the following steps:

- a) co-transfecting into a suitable cell of a plasmid including a reporter gene and an expression plasmid coding for said protein;
- b) expressing said protein;
- c) treating said cell with serum starvation to reduce mitogenic activity;
- d) applying said molecule which ligates to said protein in a serum free medium; and
- e) measuring the activity of the reporter.

25

30

Figure 1

hedg-6 cDNA and predicted amino acid sequence. The cloning sites and poly(A) tail have been excluded from this figure.

Figure 1A

SEQ. ID NO:1

```

CGCTCCCGCCGCGAGTCGCCGGGCCATGGGCCTCGAGCCCGCCCGAACCCCGCGAGCCC
GCGAGGGCGGGCGTCAGCGGCCCGGTACCCGAGCTCGGGCGGGGCTTGGGGGCGCTCGGG
1  -----+-----+-----+-----+-----+-----+-----+

```

Figure 1B

SEQ. ID NO:2

```

M V I M G Q C Y Y N
GCCTTGCTGCGGCGTGACTGGAGGCCAGATGGTCATCATGGGCCAGTGCTACTACAAC
CGGAACAGACGCCGCACTGACCTCCGGGTCTACCAGTAGTACCCGGTCACGATGATGTTG
61 -----+-----+-----+-----+-----+-----+-----+
120

E T I G F F Y N N S G K E L S S H W R P
GAGACCATCGGTTTCTTCTATAACAACAGTGCCAAAGAGCTCAGCTCCCACTGGCGGGCCC
CTCTGGTAGCCAAAGAAGATATTGTTGTCACCGTTTCTCGAGTCGAGGGTGACCGCCGGG
121 -----+-----+-----+-----+-----+-----+-----+
180

K D V V V V A L G L T V S V L V L L T N
AAGGATGTGGTCGTGGTGGCACTGGGGCTGACCGTCAGCGTGCTGGTGCTGCTGACCAAT
TTCCTACACCAGACCACCGTGACCCCGACTGGCAGTCGCACGACCACGACGACTGGTTA
181 -----+-----+-----+-----+-----+-----+-----+
240

L L V I A A I A S N R R F H Q P I Y Y L
CTGCTGGTCATAGCAGCCATCGCCTCCAACCGCCGCTTCCACCAGCCCATCTACTACCTG
GACGACCAGTATCGTCGGTAGCGGAGGTTGGCGGCGAAGGTGGTCGGGTAGATGATGGAC
241 -----+-----+-----+-----+-----+-----+-----+
300

L G N L A A A D L F A G V A Y L F L M F
CTCGGCAATCTGGCCGCGGCTGACCTCTTCGCGGGCGTGCCCTACCTCTTCCTCATGTTT
GAGCCGTTAGACCGGCGCCGACTGGAGAAGCGCCCGCACC GGATGGAGAAGGAGTACAAG

```

301 -----+-----+-----+-----+-----+-----+ 360

H T G P R T A R L S L E G W F L R Q G L
CACACTGGTCCCCGCACAGCCCGACTTTCACCTGAGGGCTGGTTCCTGCGGCAGGGCTTG
GTGTGACCAGGGGCGTGTGCGGGCTGAAAGTGAAGTCCCGACCAAGGACGCCGTCCCGAAC

361 -----+-----+-----+-----+-----+-----+ 420

L D T S L T A S V A T L L A I A V E R H
CTGGACACAAGCCTCACTGCGTCGGTGGCCACACTGCTGGCCATCGCCGTGGAACGGCAC
GACCTGTGTTCGGAGTGACGCAGCCACCGGTGTGACGACCGGTAGCGGCACCTTGCCGTG

421 -----+-----+-----+-----+-----+-----+ 480

R S V M A V Q L H S R L P R G R V V M L
CGCAGTGTGATGGCCGTACAGTTGCACAGCCGCCTGCCCCGTGGCCGCGTGGTCATGCTC
GCGTCACACTACCGGCATGTCAACGTGTGCGCGGACGGGGCACCGGCGCACCAGTACGAG

481 -----+-----+-----+-----+-----+-----+ 540

I V G V W V A A L G L G L L P A H S W H
ATTGTGGGCGTGTGGGTGGCTGCCCTGGGGCTGTTGCCTGCCCACTCCTGGCAC
TAACACCCGCACACCCACCGACGGGACCCGGACCCCGACAACGGACGGGTGAGGACCGTG

541 -----+-----+-----+-----+-----+-----+ 600

C L C A L D R C S R M A P L L S R S Y L
TGCCCTGTGCCCTGGACCGCTGCTCACGCATGGCACCCCTGCTCAGCCGCTCCTATTTG
ACGGAGACACGGGACCTGGCGACGAGTGCGTACCGTGGGGACGAGTCGGCGAGGATAAAC

601 -----+-----+-----+-----+-----+-----+ 660

A V W A L S S L L V F L L M V A V Y T R
GCCGTCTGGGCTCTGTGAGCCTGCTTGTCTTCTGCTCATGGTGGCTGTGTACACCCGC
CGGCAGACCCGAGACAGCTCGGACGAACAGAAGGACGAGTACCACCGACACATGTGGGCG

661 -----+-----+-----+-----+-----+-----+ 720

I F L Y V R R R V Q R M A E H V S C H P
ATTTTTTTTATACGTGCGGCGGCGAGTGCAGCGCATGGCAGAGCATGTCAGCTGCCACCCC
TAAAAAATATGCACGCCGCCGCTCACGTGCGGTACCGTCTCGTACAGTCGACGGTGGGG
721 -----+-----+-----+-----+-----+-----+ 780
R Y R E T T L S L V K T V V I I L G A F
CGCTACCGAGAGACCACGCTCAGCCTGGTCAAGACTGTTGTCATCATCTGGGGGCGTTC
GCGATGGCTCTCTGGTGCGAGTCGGACCAGTTCTGACAACAGTAGTAGGACCCCCGCAAG
781 -----+-----+-----+-----+-----+-----+ 840

V V C W T P G Q V V L L L D G L G C E S
GTGGTCTGCTGGACACCAGGCCAGGTGGTACTGCTCCTGGATGGTTTAGGCTGTGAGTCC
CACCAGACGACCTGTGGTCCGGTCCACCATGACGAGGACCTACCAAATCCGACACTCAGG
841 -----+-----+-----+-----+-----+-----+ 900

C N V L A V E K Y F L L L A E A N S L V
TGCAATGTCTGGCTGTAGAAAAGTACTTCCTACTGTTGGCCGAGGCCAACTCACTGGTC
ACGTTACAGGACCGACATCTTTTCATGAAGGATGACAACCGGCTCCGGTTGAGTGACCAG
901 -----+-----+-----+-----+-----+-----+ 960

N A A V Y S C R D A E M R R T F R R L L
AATGCTGCTGTGTACTCTTGCCGAGATGCTGAGATGCGCCGCACCTTCCGCCGCCTTCTC
TTACGACGACACATGAGAACGGCTCTACGACTCTACGCGGCGTGGAAGGCGGCGGAAGAG
961 -----+-----+-----+-----+-----+-----+
1020

C C A C L R Q P T R E S V H Y T S S A Q
TGCTGCGCGTGCCCTCCGCCAGCCCACCCGCGAGTCTGTCCACTATACATCCTCTGCCAG
ACGACGCGCACGGAGGCGGTGCGGTGGGCGCTCAGACAGGTGATATGTAGGAGACGGGTC
1021 -----+-----+-----+-----+-----+-----+
1080

G G A S T R I M L P E N G H P L M D S T
GGAGGTGCCAGCACTCGCATCATGCTTCCCGAGAACGGCCACCCACTGATGGACTCCACC

CCTCCACGGTCGTGAGCGTAGTACGAAGGGCTCTGCCGGTGGGTGACTACCTGAGGTGG
1081 -----+-----+-----+-----+-----+-----+
1140

L *
CTTTAGCTACCTTGAACCTCAGCGGTACGCGGCAAGCAACAAATCCACAGCCCCTGATGA
GAAATCGATGGAACCTGAAGTCGCCATGCGCCGTTGTTTGGTGTCTCGGGGACTACT
1141 -----+-----+-----+-----+-----+-----+
1200

CTTGTGGGTGCTCCTGGCTCAACCCAACCAACAGGACTGACTGACCGGCAGGACAAGGTC
GAACACCCACGAGGACCGAGTTGGGTTGGTTGTCCTGACTGACTGGCCGTCCTGTTCCAG
1201 -----+-----+-----+-----+-----+-----+
1260

TGGCATGGCACAGCACTGCTGCCAGGCCTCCCAGGCACCACTCTGCCAGGGAATGG
ACCGTACCGTGTCGTGGTGACGGTCCGGAGGGTCCGTGTGGTGAGACGGGTCCCTTACC
1261 -----+-----+-----+-----+-----+-----+
1320

GGGCTTTGGGTGCTCTCCCACTGCCTGGGGGAGTCAGATGGGGTGACAGGAATCTGGCTCT
CCCGAAACCCAGTAGAGGGTGACGGACCCCCTCAGTCTACCCACGTCCTTAGACCGAGA
1321 -----+-----+-----+-----+-----+-----+
1380

TCAGCCATCCCAGGTTTAGGGGGTTTGTAACAGACATTATTCTGTTTTCACTGCGTATCC
AGTCGGTAGGGTCCAAATCCCCCAACATTGTCTGTAATAAGACAAAAGTGACGCATAGG
1381 -----+-----+-----+-----+-----+-----+
1440

TTGGTAAGCCCTGTGGACTGGTTCCTGCTGTGTGATGCTGAGGGTTTTAAGGTGGGGAGA
AACCATTCTGGGACACCTGACCAAGGACGACACACTACGACTCCCAAAATTCACCCCTCT

1441 -----+-----+-----+-----+-----+-----+
1500

GATAAGGGCTCTCTCGGGCCATGCTACCCGGTATGACTGGGTAATGAGGACAGACTGTGG
CTATTCCCGAGAGAGCCCGGTACGATGGGCCATACTGACCCATTACTCCTGTCTGACACC

1501 -----+-----+-----+-----+-----+-----+
1560

ACACCCCATYTACCTGAGTCTGATTCTTTAGCAGCAGAGACTGAGGGGTGCAGAGTGTGA
TGTGGGGTARATGGACTCAGACTAAGAAATCGTCGTCTCTGACTCCCCACGTCTCACACT

1561 -----+-----+-----+-----+-----+-----+
1620

GCTGGGAAAGGTTTGTGGCTCCTTGCAGCCTCCAGGGACTGGCCTGTCCCGATAGAATT
CGACCCCTTTCCAAACACCGAGGAACGTCGGAGGTCCCTGACCGGACAGGGGCTATCTTAA

1621 -----+-----+-----+-----+-----+-----+
1680

GAAGCAGTCCACGGGGAGGGGATGATACAAGGAGTAAACCTTTCTTTACACTCTGAGGTC
CTTCGTCAGGTGCCCCCTCCCCTACTATGTTCCCTCATTTGGAAAGAAATGTGAGACTCCAG

1681 -----+-----+-----+-----+-----+-----+
1740

TCCAAAACATTTGTTGTTATC

AGGTTTTGTAAACAACAATAG

1741 -----+-----+----- 1761

Figure 2

Nucleotide sequence of human edg-6 cDNA insert. Sequence includes the EcoRI (position 81) and NotI (position 1882) cloning sites and the 34 bp poly(A) tail

SEQ. ID NO:3

```

      TTACGAATTAATACGATCACTATAGGGAGACCAAGCTTGGTACCGAGCTCGGATCCACTA
1  -----+-----+-----+-----+-----+-----+-----+-----+ 60
      GTAACGGCCGCCAGTGTGGGGAATTCCGCTCCCGCCGAGTCGCCGGGCCATGGGCCTCG
61  -----+-----+-----+-----+-----+-----+-----+-----+ 120
      AGCCCGCCCCGAACCCCGCGAGCCCGCCTTGTCTGCGGCGTGACTGGAGGCCAGATGG
121 -----+-----+-----+-----+-----+-----+-----+-----+ 180
      TCATCATGGGCCAGTGCTACTACAACGAGACCATCGGTTTCTTCTATAACAACAGTGGCA
181 -----+-----+-----+-----+-----+-----+-----+-----+ 240
      AAGAGCTCAGCTCCCACTGGCGGCCCAAGGATGTGGTCGTGGTGGCACTGGGGCTGACCG
241 -----+-----+-----+-----+-----+-----+-----+-----+ 300
      TCAGCGTGCTGGTGCTGCTGACCAATCTGCTGGTCATAGCAGCCATCGCCTCCAACCGCC
301 -----+-----+-----+-----+-----+-----+-----+-----+ 360
      GCTTCCACCAGCCCATCTACTACCTGCTCGGCAATCTGGCCGCGGCTGACCTCTTCGCGG
361 -----+-----+-----+-----+-----+-----+-----+-----+ 420
      GCGTGGCCTACCTCTTCTCATGTTCACACTGGTCCCCGCACAGCCCGACTTTCACCTG
421 -----+-----+-----+-----+-----+-----+-----+-----+ 480
      AGGGCTGGTTCCTGCGGCAGGGCTTGCTGGACACAAGCCTCACTGCGTCGGTGGCCACAC
481 -----+-----+-----+-----+-----+-----+-----+-----+ 540
      TGCTGGCCATCGCCGTGGAACGGCACCGCAGTGTGATGGCCGTACAGTTGCACAGCCGCC
541 -----+-----+-----+-----+-----+-----+-----+-----+ 600
      TGCCCCGTGGCCGCGTGGTCACTGCTCATTGTGGGCGTGTGGGTGGCTGCCCTGGGCCTGG
601 -----+-----+-----+-----+-----+-----+-----+-----+ 660
      GGCTGTTGCCTGCCCACTCCTGGCACTGCCTCTGTGCCCTGGACCGCTGCTCACGCATGG
661 -----+-----+-----+-----+-----+-----+-----+-----+ 720
      CACCCCTGCTCAGCCGCTCCTATTGGCCGTCTGGGCTCTGTGAGCCTGCTTGTCTTCC
721 -----+-----+-----+-----+-----+-----+-----+-----+ 780
      TGCTCATGGTGGCTGTGTACACCCGCATTTTTTTATACGTGCGGCGGAGTGCAGCGCA
781 -----+-----+-----+-----+-----+-----+-----+-----+ 840
      TGGCAGAGCATGTCAGCTGCCACCCCGCTACCGAGAGACCAGCTCAGCCTGGTCAAGA
841 -----+-----+-----+-----+-----+-----+-----+-----+ 900
      CTGTTGTCATCATCCTGGGGGCGTTTCGTGGTCTGCTGGACACCAGGCCAGGTGGTACTGC
901 -----+-----+-----+-----+-----+-----+-----+-----+ 960
      TCCTGGATGGTTTAGGCTGTGAGTCCTGCAATGTCCTGGCTGTAGAAAAGTACTTCCTAC
961 -----+-----+-----+-----+-----+-----+-----+-----+ 1020
      TGTGGCCGAGGCCAACTCACTGGTCAATGCTGCTGTGTACTCTTGCCGAGATGCTGAGA
1021 -----+-----+-----+-----+-----+-----+-----+-----+ 1080
      TGGCCCGCACCTTCCGCCGCTTCTCTGCTGCGCGTGCCTCCGCCAGCCACCCGCGAGT
1081 -----+-----+-----+-----+-----+-----+-----+-----+ 1140

```

1141 CTGTCCACTATACATCCTCTGCCCAGGGAGGTGCCAGCACTCGCATCATGCTTCCOGAGA
-----+-----+-----+-----+-----+-----+ 1200

1201 ACGGCCACCCACTGATGGACTCCACCCTTTAGCTACCTTGAACCTCAGCGGTACGCGGCA
-----+-----+-----+-----+-----+-----+ 1260

1261 AGCAACAAATCCACAGCCCCTGATGACTTGTGGGTGCTCCTGGCTCAACCCAACCAACAG
-----+-----+-----+-----+-----+-----+ 1320

1321 GACTGACTGACCGGCAGGACAAGGTCTGGCATGGCACAGCACTGCCAGGCCTCCCCA
-----+-----+-----+-----+-----+-----+ 1380

1381 GGCACACCACTCTGCCCAGGGAATGGGGCTTTGGGTACATCTCCCACTGCCTGGGGGAGT
-----+-----+-----+-----+-----+-----+ 1440

1441 CAGATGGGGTGCAGGAATCTGGCTCTTCAGCCATCCCAGGTTTAGGGGGTTTGTAACAGA
-----+-----+-----+-----+-----+-----+ 1500

1501 CATTATTCTGTTTTCACTGCGTATCCTTGGTAAGCCCTGTGGACTGGTTCCTGCTGTGTG
-----+-----+-----+-----+-----+-----+ 1560

1561 ATGCTGAGGGTTTTAAGGTGGGAGAGATAAGGGCTCTCTCGGGCCATGCTACCCGGTAT
-----+-----+-----+-----+-----+-----+ 1620

1621 GACTGGGTAATGAGGACAGACTGTGGACACCCCATYTACCTGAGTCTGATTCTTTAGCAG
-----+-----+-----+-----+-----+-----+ 1680

1681 CAGAGACTGAGGGGTGCAGAGTGTGAGCTGGGAAAGGTTTGTGGCTCCTTGACGCTCCA
-----+-----+-----+-----+-----+-----+ 1740

1741 GGGACTGGCCTGTCCCCGATAGAATTGAAGCAGTCCACGGGGAGGGGATGATACAAGGAG
-----+-----+-----+-----+-----+-----+ 1800

1801 TAAACCTTTCTTTACACTCTGAGGTCTCCAAAACATTTGTTGTTATCAAAAAAAAAAAAAA
-----+-----+-----+-----+-----+-----+ 1860

1861 AAAAAAAAAAAAAAAAAAAAAAGCGCCGC
-----+-----+-----+-----+-----+-----+ 1889

INTERNATIONAL SEARCH REPORT

Interr. nal Application No

PCT/CA 98/00487

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C12N5/10 C07K16/28 G01N33/563
G01N33/50 A61K31/70 A01K67/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N G01N A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 30406 A (CAO LIANG ; HUMAN GENOME SCIENCES INC (US); LI YI (US); NI JIAN (US) 3 October 1996	1-4, 6-8, 10-27, 31
Y	see the whole document	28-30
Y	WO 97 00952 A (INCYTE PHARMA INC) 9 January 1997	28-30
A	see the whole document	
	HECHT J H ET AL: "VENTRICULAR ZONE GENE-1 (VZG-1) ENCODES A LYSOPHOSPHATIDIC ACID RECEPTOR EXPRESSED IN NEUROGENIC REGIONS OF THE DEVELOPING CEREBRAL CORTEX" THE JOURNAL OF CELL BIOLOGY, vol. 135, no. 4, November 1996, pages 1071-1083, XP002046888 cited in the application	1-36
	see the whole document	

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 October 1998

Date of mailing of the international search report

27/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/00487

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>AN S ET AL: "MOLECULAR CLONING OF THE HUMAN EDG2 PROTEIN AND ITS IDENTIFICATION AS A FUNCTIONAL CELLULAR RECEPTOR FOR LYSOPHOSPHATIDIC ACID" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 231, no. 3, 24 February 1997, pages 619-622, XP002046899 cited in the application see the whole document</p>	1-36
P,X	<p>--- LAMERDIN, J.E., ET AL. : "untitled" EMBL SEQUENCE DATA LIBRARY, 1 July 1997, XP002080863 heidelberg, germany accession no. 000543</p>	21
E	<p>--- EP 0 855 443 A (SMITHKLINE BEECHAM CORP) 29 July 1998 see the whole document -----</p>	1-29, 31

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/CA 98/00487

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9630406	A	03-10-1996	AU 2236895 A EP 0817800 A	16-10-1996 14-01-1998
WO 9700952	A	09-01-1997	AU 6388696 A CA 2224799 A EP 0840787 A	22-01-1997 09-01-1997 13-05-1998
EP 0855443	A	29-07-1998	JP 10210993 A	11-08-1998